Login to Your Account

Despite Tough Market, Aldagen's IPO Seeks $81M for Cell Therapy

By Jennifer Boggs

Tuesday, May 13, 2008
With its lead cell therapy program in a pivotal study, Aldagen Inc. has decided to brave the public markets. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription